Decentralized Clinical Trials
Decentralized clinical trials (DCTs) move trial activities out of the traditional site and toward the participant — remote visits, telehealth assessments, local labs, direct-to-patient investigational product shipping, wearables and eConsent. The design intent is access and retention, but every decentralized element still has to satisfy the same GCP obligations for participant safety and data reliability. ICH E6(R3) is the first ICH GCP text written to be technology-agnostic and fit-for-purpose, which is why it is the natural home for DCT design.
What an explainer is not
A topic explainer is SPEQ’s synthesis of what a practice involves, cited to the standards that govern it. It does not reproduce their text, and it does not determine which of them apply to your product or process.
[ POSITION IN THE FRAMEWORK ]
7 DIMENSIONS · 24 LINKSDecentralized trials move activities toward the participant — remote visits, telehealth, direct-to-patient shipping, eConsent — but each element still owes the same GCP duties, under ICH E6(R3)'s technology-neutral quality-by-design frame.
06 · QUALITY MATURITY — DECENTRALIZED CLINICAL TRIALS, REACTIVE TO ADAPTIVE
Decentralized elements are bolted on operationally with no protocol rationale, data-flow map, or defined controls.
DCT methods are used, but eConsent, telehealth, and DTP shipping are governed inconsistently and validation is patchy.
Each remote element has a documented rationale, data-flow map, and defined controls that preserve safety and data quality.
Distributed data integrity is monitored across systems and vendors; DTP chain-of-custody and remote safety detection are proven.
Decentralization is a risk-based design decision in the protocol, with quality-by-design applied element by element.
SPEQ’s shared five-stage progression, labelled synthesis — not the FDA QMM rating scale. Where does your organization sit? Score your quality system →
07 · REGULATORY & EVIDENCE
GOVERNING STANDARDS · 4
Derived from the 4 standards SPEQ maps to this subject, across 3 regulatory bodies: ICH, FDA, EMA.
RECORDS & OBJECTIVE EVIDENCE
- A protocol rationale and data-flow map for each decentralized element
- Validated eConsent, ePRO/eCOA, and wearable systems meeting Part 11/Annex 11
- DTP chain-of-custody, temperature-monitoring, and reconciliation records
- A delegation log with qualification and training for home-nursing and local providers
- Defined remote adverse-event detection, grading, and escalation procedures
COMMON INSPECTION FINDINGS
- A remote data point not reconstructable back to its origin
- eConsent unable to demonstrate the participant reviewed the current approved version
- DTP product with uncontrolled storage, temperature, or reconciliation
- Local providers performing trial tasks absent from the delegation log
- A wearable or app overwriting raw readings, breaking the audit trail
What "decentralized" actually changes
A DCT is not a trial type; it is a set of design choices about where and how each trial activity happens. Any activity that historically occurred at an investigator site — screening, consent, dosing, safety assessment, sample collection, source documentation — can be relocated to the participant's home, a local healthcare provider, a telehealth link, or a connected device. A trial may decentralize one element (direct-to-patient shipping only) or many. The regulatory obligations do not move with the activity: the investigator remains responsible for the conduct at their site of record, and the sponsor remains responsible for oversight of the whole system, no matter how distributed it is.
The FDA frames the core question as whether the decentralized element preserves data quality and participant safety relative to the on-site equivalent, per its final guidance on decentralized clinical trials for drugs, biological products, and devices. That is a risk-based determination, not a blanket permission, and it is made per element and per protocol.
Quality by design under ICH E6(R3)
ICH E6(R3) rebuilds GCP around quality by design and proportionate, risk-based effort focused on the factors critical to participant protection and reliable results. This is the framework DCT designs must satisfy: identify the critical-to-quality factors, design the trial (including its decentralized elements) to protect them, and monitor with risk-based methods rather than exhaustive 100% source-data verification. The text is deliberately media- and technology-neutral so that eConsent, telehealth and remote source data are governed by the same principles as their paper-and-clinic equivalents.
For a sponsor this means the DCT decision belongs in the protocol and the risk assessment, not in an operational afterthought. Each remote element needs a documented rationale, a data-flow map, and defined controls — who performs the activity, how identity and eligibility are confirmed, how the data reaches the trial record, and how errors are detected. SPEQ synthesis: the practical test is whether an inspector could reconstruct each remote data point back to its origin with the same confidence as an on-site record.
Investigational product logistics and safety oversight
Direct-to-participant (DTP) shipping is the highest-risk decentralized element because it touches product accountability, chain of custody, storage conditions and blinding. The sponsor must be able to show that the product shipped, its temperature excursions were controlled and monitored, the participant received and stored it correctly, and unused product was reconciled — all under the investigator's accountability even though the drug never entered the site. Cold-chain data loggers and reconciliation records become GCP source documents.
Safety oversight is the other pressure point. When assessments are remote, the protocol must define how adverse events are detected, graded and escalated without an in-person clinician, and how a participant reaches emergency care. Telehealth assessments must specify what can and cannot be judged over video. Local healthcare providers who perform trial procedures are effectively delegated tasks and belong on the delegation log with documented qualification and training.
Data integrity across a distributed system
DCTs multiply the number of systems that touch trial data — eConsent platforms, ePRO/eCOA apps, wearables, home-nursing tablets, local lab portals — and each is a computerised system that must satisfy ALCOA+ and the applicable Part 11 / Annex 11 expectations. The sponsor needs validated systems, controlled access, attributable and contemporaneous capture, and complete audit trails that survive across integrations. A wearable that overwrites raw readings, or an eConsent platform that cannot demonstrate the participant reviewed the current version, is a data-integrity finding regardless of how convenient the tool is.
The governing regulations for the trial record remain 21 CFR Parts 312 and 50/56 in the US and the Clinical Trials Regulation, EU Regulation (EU) No 536/2014, in the EU. DCT does not create a lighter evidentiary standard; it creates more places where the standard has to be enforced.
FREQUENTLY ASKED
Are decentralized trials allowed under current GCP?
Yes. Both FDA and EMA have issued guidance and recommendation papers describing how DCT elements fit existing law, and ICH E6(R3) is written to be technology-agnostic so remote and connected methods are accommodated. Nothing about decentralization relaxes the underlying obligations for participant safety and data reliability.
Who is responsible when a nurse visits a participant at home?
The home-nursing visit is a delegated trial task. The investigator retains responsibility for it, the personnel performing it must be qualified and trained and appear on the delegation log, and the activity must be documented as source data. Delegation to a third-party vendor does not transfer accountability.
Does direct-to-patient shipping break product accountability?
Only if it is not controlled. DTP shipping is permissible when chain of custody, storage conditions, temperature monitoring, receipt confirmation and reconciliation of unused product are documented under the investigator's accountability. The bar is the same as site-dispensed product; the logistics are just harder.
How does eConsent stay compliant?
The eConsent system must present the current IRB/EC-approved version, confirm the participant's identity and comprehension, capture an attributable and timestamped signature, and retain a complete audit trail — all as a validated computerised system meeting Part 11 / Annex 11. eConsent is convenience layered on the same consent obligations, not a substitute for them.